02	13. (Amended) A carrier according to claim 1 in combination with a minor
	capsid protein L2 of human papillomavirus (HPV-L2 protein).
	
N3	16. (Amended) A carrier according to claim 1 in which said substance is an
	oligo- or polynucleotide.
	18. (Amended) A vaccine, comprising as an active ingredient a carrier as
1 <u>11</u>	defined in claim 1.
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Solinos in ciami 1.
	19. (Amended) A polynucleotide coding for the carrier as defined in claim 1.
=== T	
Ď	
ر <u>ت</u> ت	21. (Amended) A method of preventing or treating viral, bacterial or parasite
	infections by veccination with a corrier as defined in claim 1
	infections by vaccination with a carrier as defined in claim 1.
	
0.00	23. (Amended) A method of preventing or treating development of benign or
Oh	malign consequences of human papillomavirus infection by vaccination with a carrier as
0	mangh consequences of human papinomavitus infection by vaccination with a carrier as
	defined in claim 1.
N1	25. (Amended) A method of preventing or treating cancer by vaccination with a
\mathcal{K}'	
	carrier as defined in claim 1.

- 27. (New) A carrier according to claim 7, capable of giving rise to a protective antibody response.
- 28. (New) A carrier according to slaim 8, capable of giving rise to a protective antibody response.

THE STATE OF